Followers | 505 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
![](https://investorshub.advfn.com/uicon/475374.png?cb=1683825270)
Sunday, December 06, 2015 1:43:16 PM
bullish 100.28
falling wedge breakout
bullish engulfing candle
## source: finance.yahoo.com
Sat, 05 Dec 2015 18:17:33 GMT ~ Is Ultragenyx Pharmaceutical Inc (RARE) Going to Burn These Hedge Funds?
read full: http://www.insidermonkey.com/blog/is-ultragenyx-pharmaceutical-inc-rare-going-to-burn-these-hedge-funds-397331/
*********************************************************
Thu, 03 Dec 2015 13:30:00 GMT ~ Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Adults With X-Linked Hypophosphatemia (XLH)
[GlobeNewswire] - NOVATO, Calif., Dec. 03, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-first-patient-enrolled-133000975.html
*********************************************************
Wed, 02 Dec 2015 21:30:00 GMT ~ Ultragenyx to Present at the Oppenheimer Annual Healthcare Conference
[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, ...
read full: http://finance.yahoo.com/news/ultragenyx-present-oppenheimer-annual-healthcare-213000446.html
*********************************************************
Wed, 02 Dec 2015 13:30:00 GMT ~ Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...
read full: http://finance.yahoo.com/news/ultragenyx-reports-positive-interim-40-133000458.html
*********************************************************
Wed, 18 Nov 2015 18:04:24 GMT ~ ULTRAGENYX PHARMACEUTICAL INC. Financials
read full: http://finance.yahoo.com/q/is?s=rare
*********************************************************
$RARE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RARE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
$RARE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RARE extra dd links
Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
Recent RARE News
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/20/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 06:23:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 06:22:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 06:22:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 10:31:31 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 09:11:24 PM
- Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/14/2024 12:49:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:47:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 09:20:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 09:10:24 PM
- Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/12/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:04:10 PM
- Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) • GlobeNewswire Inc. • 06/12/2024 08:00:00 PM
- Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) • GlobeNewswire Inc. • 06/11/2024 09:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 11:58:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 09:20:10 PM
- Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:04:17 PM
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) • GlobeNewswire Inc. • 05/30/2024 08:00:00 PM
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/17/2024 08:30:00 PM
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference • GlobeNewswire Inc. • 05/07/2024 08:30:00 PM
- Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 05/02/2024 08:00:00 PM
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease • GlobeNewswire Inc. • 04/30/2024 08:00:00 PM
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 04/25/2024 08:30:00 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM